Alexion Pharmaceuticals, Inc. (ALXN) EPS Estimated At $1.10

July 18, 2017 - By Migdalia James

 Alexion Pharmaceuticals, Inc. (ALXN) EPS Estimated At $1.10
Investors sentiment is 1.07 in Q4 2016. Its the same as in 2016Q3. It is the same, as 59 investors sold Alexion Pharmaceuticals, Inc. shares while 167 reduced holdings. only 81 funds opened positions while 160 raised stakes. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported.
Walleye Trading has invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Amer Century Companies Inc holds 0.17% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 1.28M shares. Gateway Invest Advisers Ltd Co has 166,404 shares for 0.19% of their portfolio. Edgewood Management Ltd Liability Corp has invested 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Ancora Ltd Limited Liability Company has invested 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Palisade Capital Management Lc Nj accumulated 3,000 shares. Partner Fund L P owns 0.46% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 133,605 shares. Daiwa Grp Inc holds 5,900 shares or 0% of its portfolio. Fort Washington Invest Advsrs Oh accumulated 7,355 shares. Panagora Asset Mgmt holds 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 9,785 shares. Point72 Asset Management Limited Partnership invested 0.34% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 2,020 are owned by Highstreet Asset Mgmt Inc. Eton Park Mgmt Limited Partnership has 0.49% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 202,000 shares. Proshare Limited holds 0.27% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 195,782 shares. Fukoku Mutual Life Insurance holds 1,000 shares or 0.02% of its portfolio.

Since February 6, 2017, it had 4 buys, and 23 selling transactions for $230.27 million activity. 2,728 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares with value of $342,904 were sold by MACKAY MARTIN. Wagner Heidi L had sold 1,932 shares worth $243,371 on Monday, February 6. On Monday, February 27 the insider O’Neill Julie sold $206,841. $1.17 million worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was bought by HANTSON LUDWIG on Wednesday, June 14. COUGHLIN CHRISTOPHER J had bought 2,000 shares worth $234,200. Shares for $131,357 were sold by Miller Edward.

Analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report $1.10 EPS on July, 27.They anticipate $0.17 EPS change or 18.28 % from last quarter’s $0.93 EPS. ALXN’s profit would be $246.62M giving it 28.59 P/E if the $1.10 EPS is correct. After having $1.20 EPS previously, Alexion Pharmaceuticals, Inc.’s analysts see -8.33 % EPS growth. The stock decreased 0.73% or $0.93 during the last trading session, reaching $125.78. About 927,063 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since July 18, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 24 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 17 have Buy rating, 0 Sell and 7 Hold. Therefore 71% are positive. Alexion Pharmaceuticals Inc. had 57 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Equal-Weight” rating by Barclays Capital on Thursday, February 4. Barclays Capital maintained the stock with “Equal-Weight” rating in Friday, July 29 report. Stifel Nicolaus maintained it with “Buy” rating and $15700 target in Friday, June 23 report. BMO Capital Markets maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, June 13 with “Buy” rating. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Citigroup on Monday, June 27. The rating was initiated by Suntrust Robinson with “Buy” on Thursday, January 7. The firm has “Outperform” rating by Leerink Swann given on Monday, September 26. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Hold” rating by Jefferies on Wednesday, June 7. BMO Capital Markets initiated the shares of ALXN in report on Thursday, April 7 with “Market Perform” rating. Citigroup initiated Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, February 25 with “Neutral” rating.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $28.20 billion. The Firm is focused on the development and commercialization of therapeutic products. It has a 59.73 P/E ratio. The Company’s products include Soliris , Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Gurufocus.com which released: “Factory Mutual Insurance Co Buys Alexion Pharmaceuticals Inc, SPDR Series …” on July 10, 2017, also Benzinga.com with their article: “Exclusive: Alexion Responds To Government Probe” published on July 06, 2017, Seekingalpha.com published: “Alexion higher after posting Strensiq update” on July 05, 2017. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Nasdaq.com and their article: “Alexion Pharma: CHMP Issues Positive Opinion For Soliris – Quick Facts” published on June 23, 2017 as well as Barrons.com‘s news article titled: “Alexion Pharmaceuticals: Nothing to See Here?” with publication date: July 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.